-- Preview Email Newsletter
| Journals Medical Newsletter for 2026-10-26 ( 3 items ) |
|
Governor Hochul Announces Increased State Police and Local Law Enforcement Patrols to Combat Impaired and Reckless Driving Through Halloween (10)
ALBANY, New York, Oct. 24 -- Gov. Kathy Hochul, D-New York, issued the following news release:
* * *
Governor Hochul Announces Increased State Police and Local Law Enforcement Patrols to Combat Impaired and Reckless Driving Through Halloween
*
Traffic Enforcement and Patrol Period Begins Sunday and Will Run Through Saturday, Oct. 31
Governor Urges New Yorkers To Stay Vigilant and Not Drive Impaired; Halloween Is the Deadliest Day for Pedestrians Under the Age of 18
44,545 Citations Issued During 2025 Enforcement
Governor Kathy Hochul tod more PR
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 (10)
BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Immunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026
*
Results suggest that introducing tarlatamab, a bispecific T-cell engager, earlier in treatment could meaningfully extend survival for a broader group of patients
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecif more PR
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death (10)
BOSTON, Massachusetts, Oct. 24 [Category: BizHospital] -- The Dana-Farber Cancer Institute issued the following news release:
* * *
Perioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death
*
New analysis provides additional evidence on how the PROTEUS regimen compares with standard of care.
An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide -- a next-generation neoadjuv more PR
|
